Business, energy, technology, markets and global industry news from Business News Today

Actinium-225

PharmaDeviceNews Actinium-225
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone

Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.

Read More
GE HealthCare’s StarGuide GX 4D SPECT/CT is designed for expanding theranostics workflows and emerging radionuclides including investigational alpha emitters. Representative image.
Features & Analysis

GE HealthCare designed StarGuide GX for the radiopharma boom. Is SPECT/CT becoming treatment infrastructure?

GE HealthCare has moved StarGuide GX toward the U.S. market as radiopharmaceutical therapy expands beyond conventional nuclear medicine. The 4D CZT SPECT/CT system is designed to image across a wide energy range, including investigational alpha emitters, highlighting how the theranostics boom is creating demand not just for drugs but for quantitation, dosimetry and workflow infrastructure.

Read More
Radiopharmaceutical cancer therapy advances as the US Food and Drug Administration clears Full-Life’s actinium-225 FL-261 for Phase 1 clinical testing in c-MET-positive lung cancer, expanding the company’s targeted oncology pipeline. Representative image.
Pharma & Biotech

Full-Life wants to carry actinium-225 directly to c-MET tumors. Can FL-261 widen targeted alpha therapy beyond prostate cancer?

FDA clears Full-Life’s actinium-225 FL-261 for Phase 1 testing in c-MET-positive lung cancer as the radiopharmaceutical company expands its pipeline.

Read More
Radiotheranostics combines molecular imaging with targeted radioactive drugs, allowing clinicians to identify tumors carrying the therapeutic target before delivering systemic radiation treatment. Representative image.
Features & Analysis

Lutetium, actinium and the next isotope race: inside radiopharmaceutical cancer therapy

Radiotheranostics pairs molecular imaging with targeted radioactive drugs, allowing clinicians to confirm whether a tumor carries the therapeutic target before delivering radiation systemically.

Read More
Actinium Pharmaceuticals is strengthening Actimab-A intellectual property and manufacturing capabilities as the Actinium-225 radiotherapy program advances toward later-stage development in acute myeloid leukemia. Representative image.
Pharma & Biotech

Actinium expands Actimab-A intellectual property as Actinium-225 manufacturing becomes a strategic priority

Actinium advances Actimab-A IP and manufacturing while NYSE American compliance adds a parallel financing and execution test.

Read More
Representative image of a clinician reviewing prostate cancer imaging in a modern nuclear medicine setting, reflecting Convergent Therapeutics’ CONV01-α Phase 2 data and the growing race to develop Actinium-225 radiopharmaceuticals for post-Lu-PSMA metastatic prostate cancer.
Pharma & Biotech

Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?

CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.

Read More
Representative image: Actinium Pharmaceuticals’ ATNM-400 update and new Actimab-A and Iomab-ACT patent allowances underscore rising investor and clinical interest in targeted radiotherapy, actinium-225 cancer treatments and next-generation radiopharmaceuticals.
Pharma & Biotech

Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026

Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.

Read More
Representative image: A sterile radiopharmaceutical manufacturing cleanroom with shielded processing equipment and sealed vials, illustrating how Niowave’s Michigan Actinium-225 facility could support the next phase of targeted cancer therapy supply.
Pharma & Biotech

Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?

Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.

Read More
Pharma & Biotech

How Full-Life Technologies is using US$150m to push beyond platform promise

Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.

Read More
Pharma & Biotech

Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer

Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.

Read More